Market News & Trends
Concert Pharmaceuticals Achieves $2-Million Milestone From Avanir Pharmaceuticals
Concert Pharmaceuticals, Inc. recently announced it has achieved a $2-million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the progression of…
GENFIT Announces Pivotal Phase III Clinical Trial
GENFIT recently announced the design of the global Phase III trial to evaluate the benefits of Elafibranor treatment on NASH patients. The pivotal trial will…
Baxter Completes Capacity Expansion to Support Oncology Contract Manufacturing Services
Baxter International Inc.’s BioPharma Solutions business, a premier contract manufacturing organization (CMO) that specializes in parenteral pharmaceuticals, recently announced it has completed an approximately 1,800-square-meter…
Xenetic Biosciences Enters Into Asset Purchase Agreement
Xenetic Biosciences, Inc. recently announced it has entered into an Asset Purchase Agreement with AS Kevelt and OJSC Pharmsynthez. Pursuant to the APA, the Sellers…
Adare Pharmaceuticals Partners With Cincinnati Children’s on Innovation Fund
Adare Pharmaceuticals, Inc. and the Cincinnati Children’s Hospital Medical Center recently announced they are partnering together on an Innovation Fund, which will focus on optimizing…
Aptose Biosciences Announces Collaborations for New Multi-Targeting Epigenetic Therapeutic Agents
Aptose Biosciences Inc. recently announced two collaborations that will provide exclusive access to new epigenetic therapeutics for the company's oncology pipeline. These partnerships have been…
Resverlogix Commences Dosing in Phase II Clinical Trial
Resverlogix Corp. recently announced that the first patient has been randomized and dosing has commenced in the Phase III clinical trial BETonMACE with lead drug…
NightstaRx Announces Start of Miami Gene Therapy Study
NightstaRx Ltd recently announced that the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine, has begun enrolling and dosing subjects…
Juniper Pharma Adds Three New Products to Its Proprietary Pipeline
Juniper Pharmaceuticals, Inc. recently announced details of its portfolio pipeline, focused on three new product candidates to treat women's health conditions, at its Investor Day…
Cancer Genetics Announces Closing Of $12 Million Public Offering
Cancer Genetics, Inc. recently confirmed the closing of its previously announced public offering of 3,000,000 shares of its common stock with 5-year warrants to purchase…
Epic Sciences Partners With University of Pennsylvania's Abramson Cancer Center
Epic Sciences, Inc. recently announced a collaboration with the Abramson Cancer Center of the University of Pennsylvania (Penn) on multiple studies to explore biomarkers, identified…
12th Annual BioProcess International Conference & Exposition Is Largest in Its History
- Global Forum Focused On Advancing Drug Candidates Closer to Approval Faster and More Efficiently Sets Attendance, Exhibitor…
Planbox & Novatek International Announce Exclusive Agile Innovation Partnership for Life Sciences
Planbox has entered into an exclusive worldwide strategic partnership agreement for Planbox Innovate (formerly BrainBank Innovation Management Software), which will be marketed as NOVA-INNOVATE by…
Johnson & JohnsonAnnounces Agreement to Acquire Novira Therapeutics
Johnson & Johnson recently announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment…
First Patient Dosed in Clinical Trial of Halozyme’s Investigational Drug in Combination With Merck’s Immuno-Oncology Drug
Halozyme Therapeutics, Inc. recently announced the first patient has received its investigational new drug, PEGPH20 in combination with Merck's KEYTRUDA (pembrolizumab) in a clinical trial…
FDA Grants Fast-Track Designation for Development of CAM2038, Long-Acting Buprenorphine Injections to Treat Opioid Addiction
Braeburn Pharmaceuticals and Camurus recently announced that the US FDA granted Fast-Track designation for the CAM2038 weekly and monthly buprenorphine subcutaneous injection products under development…
Espero Pharmaceuticals Announces FDA Acceptance of NDA
Espero Pharmaceuticals, Inc., recently announced that the US FDA has accepted for review the New Drug Application (NDA) for GoNitro for acute relief of an…
Xcelience Opens New Headquarters Facility
TAMPA, FLORIDA (October 30, 2015)- Xcelience is proud to announce the grand opening of its new 71,000 square foot headquarters located at 4910 Savarese Circle…
Dow Corning Launches New Portfolio of Topical Ingredients to Help Customers Advance Innovations in Consumer Health Care Applications
Dow Corning, a global leader in silicones, silicon-based technology and innovation, unveiled at the American Association of Pharmaceutical Scientists’ (AAPS) 2015 Annual Meeting and Exhibition…
CytoDyn Injects First Patient in Its Current Phase III Study
CytoDyn Inc. recently announced that the first patient in its Phase III clinical trial has been injected with PRO 140, the company's monoclonal antibody for…
